PNF21 is primarily investigated for its potential anti-inflammatory and immunosuppressive properties. It is being studied for its application in treating autoimmune diseases, such as rheumatoid arthritis and lupus, due to its ability to modulate immune responses. Additionally, research is exploring its use in managing chronic inflammatory conditions, including asthma and inflammatory bowel disease, where it may help reduce inflammation and alleviate symptoms. PNF21 is also being examined for its role in cancer therapy, particularly in targeting inflammation-related pathways that contribute to tumor growth. Its unique farnesyl group may enhance its efficacy and specificity in these therapeutic areas.